The addition of everolimus to trastuzumab plus paclitaxel in the HR‐negative, HER2+ breast cancer patients in the BOLERO‐1 study showed a clinically relevant progression‐free survival (PFS) prolongation of 7.2 months compared to patients without everolimus 11, although this difference did not cross the protocol‐specified significance threshold of p = 0.0044. Here, ERBB2 is linked to breast carcinoma.